Anthony Palmieri, RPh, PharmD, MBA

Generic atorvastatin led to an increase in generic dispensing rate and a reduction in the cost of treatment for patients requiring cholesterol-lowering treatment. The upcoming introduction of the PCSK9 inhibitor may change this trend.

HIV is of interest among many in managed care. This paper focuses on the costs and demographic characteristics associated with new HIV therapy initiators.